Figure 1



Figure 2A



Figure 2B



Figure 3



Figure 4A



Figure 4B



Figure 5



Figure 6


100
90
80
70
60
50
40
30
20
10
0
2760
2770
2780
2790
2800
2810
2820
2830
2840
A
B
C
D
G
A
B
C
D

Figure 7


5000000
4000000
3000000
2000000
1000000
Viability [ATP RLU]
untreated
tetrameric anti-Her2
dimeric anti-Her2
trastuzumab
0,01
0,1
1
10
100
1000
Antibody [nM]

Figure 8A


RU
160
140
120
100
80
60
40
20
0
-20
-100
0
100
200
300
400
500
600
Response (0 = capture_baseline)
Time (0 = capture_baseline)
s
dimeric anti-Her2
tetrameric anti-Her2
anti-digoxigenin
trastuzumab

Figure 8B


RU
300
250
200
150
100
50
0
-50
Response (0 = capture_baseline)
-100
0
100
200
300
400
500
600
Time (0 = capture_baseline)
s
dimeric anti-Her2
tetrameric anti-Her2
anti-digoxigenin
trastuzumab

Figure 9

A)


100,00
80,00
60,00
40,00
20,00
,00
-20,00
% ADCC
0,01
0,1
1
10
100
nM
dimeric anti-Her2
tetrameric anti-Her2
trastuzumab

B)


120,00
100,00
80,00
60,00
40,00
20,00
,00
-20,00
% ADCC
0,01
0,1
1
10
100
nM

Figure 10



Figure 11

A



B



Figure 12



Figure 13



Figure 14



Figure 15


mAU
550
500
450
400
350
300
250
200
150
100
50
0
1A2
1A4
1A6
1A8
1A10
1A12
1B2
1B4
1B6
1B8
1B10
1B12
1C2
1C4
1C6
1C8
Waste(F
35
40
45
50
55
60
65
70
75
80
85
90
ml